Holen Sie sich die Stockscreener-App
65.37
3.73%
2.35
Schlusskurs vom Vortag:
$63.02
Offen:
$63.71
24-Stunden-Volumen:
2.72M
Relative Volume:
2.17
Marktkapitalisierung:
$5.19B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-11.01
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+10.82%
1M Leistung:
+17.68%
6M Leistung:
+39.89%
1J Leistung:
+84.82%
1-Tages-Spanne:
$63.29
$67.40
1-Wochen-Bereich:
$58.90
$67.40
52-Wochen-Spanne:
$34.57
$67.40
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
65.37 | 5.01B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Will PTC Therapeutics Inc. rebound enough to break evenVolume Spike & Precise Buy Zone Identification - newser.com
Real time breakdown of PTC Therapeutics Inc. stock performanceBull Run & Free Safe Entry Trade Signal Reports - newser.com
Why PTC Therapeutics Inc. (BH3) stock could outperform next yearTrade Risk Report & Weekly Top Gainers Trade List - newser.com
Evaluating PTC Therapeutics Inc. with trendline analysisWeekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
Is PTC Therapeutics Inc. (BH3) stock among top earnings playsBear Alert & Low Risk High Reward Trade Ideas - newser.com
Will PTC Therapeutics Inc. (BH3) stock outperform energy sector in 20252025 Macro Impact & Consistent Income Trade Ideas - newser.com
Using AI based signals to follow PTC Therapeutics Inc.2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Ptc Therapeutics stock hits 52-week high at 63.33 USD By Investing.com - Investing.com Nigeria
Ptc Therapeutics stock hits 52-week high at 63.33 USD - Investing.com India
19,475 Stock Options, 39,060 RSUs: PTC Therapeutics Awards Major Inducement Grants to New Employees - Stock Titan
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia - insights.citeline.com
PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN
How to build a custom watchlist for PTC Therapeutics Inc.Options Play & AI Powered Market Entry Strategies - newser.com
PTC Therapeutics (PTCT): Assessing Valuation After New Huntington’s Data Shifts Competitive Landscape and Investor Sentiment - Yahoo Finance
Is PTC Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Small Investment Portfolio Growth - earlytimes.in
PTC Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Market Crushing Stock Picks - earlytimes.in
PTC Therapeutics Hits New 52-Week High of $63.19, Up 67% Yearly - Markets Mojo
PTC's utreloxastat fails Phase 2 clinical study for ALS - MSN
PTC Therapeutics (PTCT) Faces Pressure Following Compelling uniQ - GuruFocus
PTCT Shares Decline Amid Early Market Activity - GuruFocus
Strs Ohio Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Reaches New 1-Year HighTime to Buy? - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Makes New $284,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Buys Shares of 5,821 PTC Therapeutics, Inc. $PTCT - MarketBeat
CHMP maintains negative opinion on PTC Therapeutics' DMD treatment - MSN
PTC Therapeutics, Inc. $PTCT Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Harbor Capital Advisors Inc. Buys 8,042 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Sells $934,447.50 in Stock - MarketBeat
Intech Investment Management LLC Has $2 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Can PTC Therapeutics Inc expand into new markets2025 Biggest Moves & Community Shared Stock Ideas - khodrobank.com
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.68%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):